Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ 28431754 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | JNJ-28431754 30 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts. |
| Cohort 2 | EXPERIMENTAL | JNJ-28431754 100 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts. |
| Cohort 3 | EXPERIMENTAL | JNJ-28431754 300 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts. |
| Cohort 4 | EXPERIMENTAL | JNJ-28431754 600 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts. |
| Cohort 5 | EXPERIMENTAL | JNJ-28431754 at 30 mg/day, 100 mg/day, or 300 mg/day or placebo (the dose level to be determined from the prior cohort of patients tested and considered to be well tolerated). |
| Name | Type | Description |
|---|---|---|
| JNJ 28431754 | DRUG | A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16). |
| Placebo | DRUG | A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16). |
Inclusion Criteria: * Patients must have been diagnosed with Type 2 Diabetes for at least one year before screening * Patients must be taking a stable dose of oral (by mouth) anti-diabetic monotherapy or a combination of two anti-diabetic medications * Males or postmenopausal or surgically sterile ...
JNJ 28431754 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is a metabolic therapeutic that has been studied in patients with this condition to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics. The drug is currently in Phase 1 clinical development.
JNJ 28431754 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The company conducted a Phase 1 clinical trial of this investigational drug in patients with Type 2 Diabetes Mellitus.
JNJ 28431754 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and efficacy. The completed Phase 1 study involved 116 participants with Type 2 Diabetes Mellitus.
JNJ 28431754 has one completed clinical trial registered under NCT00963768, titled 'A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus.' This Phase 1 study enrolled 116 participants and was conducted in the United States, Germany, and South Korea.
Yes, JNJ 28431754 is the same as JNJ-28431754. The drug is referred to with and without a hyphen in clinical trial records and other documentation. Both names refer to the same investigational small molecule being developed for Type 2 Diabetes Mellitus.